In October 2017, Special Products Limited changed its company name to Veriton Pharma. This name change has occurred to incorporate our past heritage with our future ambitions ensuring our products continue to make a real difference to people’s lives.
The team of formulation experts at Veriton Pharma has since developed more than 60 “specials” for a targeted range of therapeutic areas. The company has grown rapidly, supplying products to more than 25 countries.
In May 2020 Veriton Pharma were acquired by SERB Pharmaceuticals, a leading European specialty pharmaceutical group focused on prescription medicines that address rare and life-threatening diseases. SERB’s focus on critical care and answering unmet needs is closely aligned with Veriton’s history and approach, and as part of an integrated group they can take their growth to the next level.
SERB acquired Veriton pharmaceuticals in 2020 to broaden its geography and product portfolio.
For over 30 years, SERB companies have made treating complex and life-threatening conditions possible, supporting clinicians, healthcare systems and governments while offering hope to patients and their families.
Licensed Products
We are committed to developing licensed medicinal products that meet the specific needs of our patients. Veriton Pharma’s portfolio of prescription medicines stems from our team’s deep expertise in the field of epilepsy.